| 体内研究: |
EVT801 (30 mg/kg; p.o.; twice daily for 7 d) shows inhibitory effect on VEGFR-3-positive tumors in mouse models, such as RT-001-HAM Subcutaneous Patient-derived xenograft (PDx) Tumor Mouse Model, 4T1 Mammary Carcinoma Mouse Model, N-diethylnitrosamine-Induced Hepatocarcinoma Mouse Model, NCI-H1703 Subcutaneous Xenograft Tumor Mouse Model, Rip1-Tag2/transgenic Mouse Models, and CT26 Ectopic Tumor Mouse Model. EVT801 is expressed in blood vessels of kidney cancer primary tumors and metastases, and in tumor cells of endothelial malignancies. |